Ampio Pharmaceuticals (NYSE:AMPE) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Ampio Pharmaceuticals (NYSE:AMPEGet Free Report) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the stock.

Ampio Pharmaceuticals Stock Performance

NYSE AMPE opened at $0.00 on Friday. The company has a market cap of $2,497.00, a price-to-earnings ratio of 0.00 and a beta of 3.73. Ampio Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $7.47.

Ampio Pharmaceuticals Company Profile

(Get Free Report)

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

Featured Articles

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.